WallStSmart

Ionis Pharmaceuticals Inc (IONS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ionis Pharmaceuticals Inc generates 142513% more annual revenue ($1.06B vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -30.9%. IONS earns a higher WallStSmart Score of 31/100 (F).

IONS

Avoid

31

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.7Quality: 4.5
Piotroski: 3/9Altman Z: -0.22

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IONSUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$165.82

Current Price

$74.48

$91.34 discount

UndervaluedFair: $165.82Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IONS1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
87.0%10/10

Revenue surging 87.0% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

IONS4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
25.702/10

Expensive relative to growth rate

Price/BookValuation
25.2x2/10

Trading at 25.2x book value

Return on EquityProfitability
-66.5%2/10

ROE of -66.5% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IONS

The strongest argument for IONS centers on Revenue Growth. Revenue growth of 87.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : IONS

The primary concerns for IONS are Piotroski F-Score, PEG Ratio, Price/Book. Debt-to-equity of 4.15 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

IONS profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

IONS is growing revenue faster at 87.0% — sustainability is the question.

RVMD generates stronger free cash flow (-356M), providing more financial flexibility.

Bottom Line

IONS scores higher overall (31/100 vs 24/100) and 87.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ionis Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?